All the news articles and press releases in one place.

Date / Time Source Ticker Company Sector Market Cap Announcement
10Jun21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma PLC - Result of AGM
02Jun21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma PLC - Further information re AGM
19May21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Conference Attendance for May 2021
04May21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Posting of Annual Report and Notice of AGM
30Apr21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Director Dealing
23Apr21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Director Dealing
15Apr21 08:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m FY 2020 Investor Presentation
14Apr21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Final Results
29Mar21 12:45 RNS DEST:LON Destiny Pharma Plc Health £20.5m Exercise of Options and Total Voting Rights
29Mar21 12:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15 RNS DEST:LON Destiny Pharma Plc Health £20.5m Exercise of Options and Total Voting Rights
29Mar21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Notice of Results
15Mar21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15 RNS DEST:LON Destiny Pharma Plc Health £20.5m Exercise of Options and Total Voting Rights
10Mar21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31 RNS DEST:LON Destiny Pharma Plc Health £20.5m Grant of Share Options
21Jan21 08:28 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma Investor Presentation
07Jan21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma: Directors Dealings
06Jan21 08:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09 RNS DEST:LON Destiny Pharma Plc Health £20.5m Grant of share options
22Dec20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Update on the recently acquired NTCD-M3 programme
01Dec20 17:23 RNS DEST:LON Destiny Pharma Plc Health £20.5m Holding(s) in Company
30Nov20 14:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Holding(s) in Company
26Nov20 10:50 RNS DEST:LON Destiny Pharma Plc Health £20.5m Result of General Meeting and Total Voting Rights
25Nov20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Result of Open Offer
09Nov20 16:25 RNS DEST:LON Destiny Pharma Plc Health £20.5m Fundraising and Acquisition
12Oct20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Clinical Study Patient Recruitment Update
17Sep20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Update on Phase 2b clinical study of XF-73
17Sep20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Notice of Results
07Sep20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Collaboration to co-develop treatment for COVID-19
11Aug20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Positive interim safety review of XF-73 phase 2b
27Jul20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Update on Phase 2b clinical study of XF-73
15Jul20 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Cancellation and Grant of Options
10Jun20 12:30 RNS DEST:LON Destiny Pharma Plc Health £20.5m Result of AGM
09Jun20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Grant awarded for Cardiff University collaboration
12May20 15:15 RNS DEST:LON Destiny Pharma Plc Health £20.5m Posting of Annual Report and Notice of AGM
04May20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Independent review supports the potential of XF-73
29Apr20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Final Results
24Apr20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Notice of Results
03Mar20 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Clinical and Business Update
20Jan20 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Update on the development of XF drug formulations
17Dec19 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Directorate Change
02Dec19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny to present at UK-China AMR Workshop
15Nov19 07:30 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Presentation at the Investival Showcase
06Nov19 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma to present at World AMR Congress
16Oct19 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Positive phase 1 results published in journal
23Sep19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Directorate Change
23Sep19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Interim Results for 6 months ended 30 June 2019
12Sep19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Notice of Results
10Sep19 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m University of Sheffield Research Collaboration
02Sep19 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m XF Drug platform data presented at EuroBiofilms
15Aug19 12:20 RNS DEST:LON Destiny Pharma Plc Health £20.5m Holding(s) in Company
31Jul19 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Presentation at Gordon Research Conference
19Jul19 15:12 RNS DEST:LON Destiny Pharma Plc Health £20.5m Holding(s) in Company
04Jun19 14:39 RNS DEST:LON Destiny Pharma Plc Health £20.5m Grant of Options
04Jun19 12:06 RNS DEST:LON Destiny Pharma Plc Health £20.5m Result of AGM
09May19 14:06 RNS DEST:LON Destiny Pharma Plc Health £20.5m Appointment of NOMAD and Joint Broker
29Apr19 14:28 RNS DEST:LON Destiny Pharma Plc Health £20.5m Posting of Annual Report and Notice of AGM
09Apr19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Final Results
05Apr19 17:06 RNS DEST:LON Destiny Pharma Plc Health £20.5m Exercise of Options
01Apr19 15:03 RNS DEST:LON Destiny Pharma Plc Health £20.5m Exercise of Options
28Mar19 18:13 RNS DEST:LON Destiny Pharma Plc Health £20.5m Exercise of Options
27Mar19 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m MedPharm to develop new XF-drug formulations
22Mar19 09:47 RNS DEST:LON Destiny Pharma Plc Health £20.5m Notice of Results
06Mar19 18:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Exercise of Options
28Jan19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Second positive phase 1 trial data for XF-73
25Jan19 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m New grant awarded under UK-China AMR programme
24Jan19 11:50 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma notes UK 5-year action plan on AMR
01Nov18 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m Research collaboration with Southampton University
25Oct18 16:05 RNS DEST:LON Destiny Pharma Plc Health £20.5m Grant of Options
25Oct18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Directorate Change
24Oct18 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m UK government highlights global threat of AMR
19Oct18 07:00 RNS-R DEST:LON Destiny Pharma Plc Health £20.5m BIA celebrates UK bioscience innovative
26Sep18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Dr Jesús González appointed Chief Medical Officer
26Sep18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Interim results for six months ended 30 June 2018
06Sep18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Directorate Change
26Jul18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Positive Phase 1 skin irritation study with XF-73
17Jul18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Research collaboration with Aston University
11Jul18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Notice of Results
21Jun18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Directorate Change
05Jun18 12:47 RNS DEST:LON Destiny Pharma Plc Health £20.5m Director/PDMR Shareholding
31May18 12:30 RNS DEST:LON Destiny Pharma Plc Health £20.5m Result of AGM
23Apr18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Posting of Annual Report and Notice of AGM
12Apr18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma announces clinical update on XF-73
12Apr18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Final Results
23Mar18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Notice of Full Year Results
22Mar18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Appointment of Joint Broker
15Mar18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m FDA Fast Track Designation for lead drug XF-73
26Feb18 07:00 RNS DEST:LON Destiny Pharma Plc Health £20.5m Destiny Pharma opens IND ahead of XF-73 US trials
Date / Time Source Company % Chg
10Jun21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03 RNS Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Result of AGM
02Jun21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Further information re AGM
19May21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00 RNS-R Destiny Pharma Plc -2.27%
Conference Attendance for May 2021
04May21 07:00 RNS Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
30Apr21 07:00 RNS Destiny Pharma Plc -2.27%
Director Dealing
23Apr21 07:00 RNS Destiny Pharma Plc -2.27%
Director Dealing
15Apr21 08:00 RNS-R Destiny Pharma Plc -2.27%
FY 2020 Investor Presentation
14Apr21 07:00 RNS Destiny Pharma Plc -2.27%
Final Results
29Mar21 12:45 RNS Destiny Pharma Plc -2.27%
Exercise of Options and Total Voting Rights
29Mar21 12:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15 RNS Destiny Pharma Plc -2.27%
Exercise of Options and Total Voting Rights
29Mar21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00 RNS Destiny Pharma Plc -2.27%
Notice of Results
15Mar21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15 RNS Destiny Pharma Plc -2.27%
Exercise of Options and Total Voting Rights
10Mar21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00 RNS Destiny Pharma Plc -2.27%
Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31 RNS Destiny Pharma Plc -2.27%
Grant of Share Options
21Jan21 08:28 RNS Destiny Pharma Plc -2.27%
Destiny Pharma Investor Presentation
07Jan21 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma: Directors Dealings
06Jan21 08:00 RNS-R Destiny Pharma Plc -2.27%
Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00 RNS Destiny Pharma Plc -2.27%
Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09 RNS Destiny Pharma Plc -2.27%
Grant of share options
22Dec20 07:00 RNS Destiny Pharma Plc -2.27%
Update on the recently acquired NTCD-M3 programme
01Dec20 17:23 RNS Destiny Pharma Plc -2.27%
Holding(s) in Company
30Nov20 14:00 RNS Destiny Pharma Plc -2.27%
Holding(s) in Company
26Nov20 10:50 RNS Destiny Pharma Plc -2.27%
Result of General Meeting and Total Voting Rights
25Nov20 07:00 RNS Destiny Pharma Plc -2.27%
Result of Open Offer
09Nov20 16:25 RNS Destiny Pharma Plc -2.27%
Fundraising and Acquisition
12Oct20 07:00 RNS Destiny Pharma Plc -2.27%
Clinical Study Patient Recruitment Update
17Sep20 07:00 RNS Destiny Pharma Plc -2.27%
Update on Phase 2b clinical study of XF-73
17Sep20 07:00 RNS Destiny Pharma Plc -2.27%
Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00 RNS Destiny Pharma Plc -2.27%
Notice of Results
07Sep20 07:00 RNS Destiny Pharma Plc -2.27%
Collaboration to co-develop treatment for COVID-19
11Aug20 07:00 RNS Destiny Pharma Plc -2.27%
Positive interim safety review of XF-73 phase 2b
27Jul20 07:00 RNS Destiny Pharma Plc -2.27%
Update on Phase 2b clinical study of XF-73
15Jul20 07:00 RNS-R Destiny Pharma Plc -2.27%
Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00 RNS Destiny Pharma Plc -2.27%
Cancellation and Grant of Options
10Jun20 12:30 RNS Destiny Pharma Plc -2.27%
Result of AGM
09Jun20 07:00 RNS Destiny Pharma Plc -2.27%
Grant awarded for Cardiff University collaboration
12May20 15:15 RNS Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
04May20 07:00 RNS Destiny Pharma Plc -2.27%
Independent review supports the potential of XF-73
29Apr20 07:00 RNS Destiny Pharma Plc -2.27%
Final Results
24Apr20 07:00 RNS Destiny Pharma Plc -2.27%
Notice of Results
03Mar20 07:00 RNS Destiny Pharma Plc -2.27%
Clinical and Business Update
20Jan20 07:00 RNS-R Destiny Pharma Plc -2.27%
Update on the development of XF drug formulations
17Dec19 07:00 RNS-R Destiny Pharma Plc -2.27%
APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00 RNS Destiny Pharma Plc -2.27%
Directorate Change
02Dec19 07:00 RNS Destiny Pharma Plc -2.27%
Destiny to present at UK-China AMR Workshop
15Nov19 07:30 RNS-R Destiny Pharma Plc -2.27%
Presentation at the Investival Showcase
06Nov19 07:00 RNS-R Destiny Pharma Plc -2.27%
Destiny Pharma to present at World AMR Congress
16Oct19 07:00 RNS-R Destiny Pharma Plc -2.27%
Positive phase 1 results published in journal
23Sep19 07:00 RNS Destiny Pharma Plc -2.27%
Directorate Change
23Sep19 07:00 RNS Destiny Pharma Plc -2.27%
Interim Results for 6 months ended 30 June 2019
12Sep19 07:00 RNS Destiny Pharma Plc -2.27%
Notice of Results
10Sep19 07:00 RNS-R Destiny Pharma Plc -2.27%
University of Sheffield Research Collaboration
02Sep19 07:00 RNS-R Destiny Pharma Plc -2.27%
XF Drug platform data presented at EuroBiofilms
15Aug19 12:20 RNS Destiny Pharma Plc -2.27%
Holding(s) in Company
31Jul19 07:00 RNS-R Destiny Pharma Plc -2.27%
Presentation at Gordon Research Conference
19Jul19 15:12 RNS Destiny Pharma Plc -2.27%
Holding(s) in Company
04Jun19 14:39 RNS Destiny Pharma Plc -2.27%
Grant of Options
04Jun19 12:06 RNS Destiny Pharma Plc -2.27%
Result of AGM
09May19 14:06 RNS Destiny Pharma Plc -2.27%
Appointment of NOMAD and Joint Broker
29Apr19 14:28 RNS Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
09Apr19 07:00 RNS Destiny Pharma Plc -2.27%
Final Results
05Apr19 17:06 RNS Destiny Pharma Plc -2.27%
Exercise of Options
01Apr19 15:03 RNS Destiny Pharma Plc -2.27%
Exercise of Options
28Mar19 18:13 RNS Destiny Pharma Plc -2.27%
Exercise of Options
27Mar19 07:00 RNS-R Destiny Pharma Plc -2.27%
MedPharm to develop new XF-drug formulations
22Mar19 09:47 RNS Destiny Pharma Plc -2.27%
Notice of Results
06Mar19 18:00 RNS Destiny Pharma Plc -2.27%
Exercise of Options
28Jan19 07:00 RNS Destiny Pharma Plc -2.27%
Second positive phase 1 trial data for XF-73
25Jan19 07:00 RNS Destiny Pharma Plc -2.27%
New grant awarded under UK-China AMR programme
24Jan19 11:50 RNS-R Destiny Pharma Plc -2.27%
Destiny Pharma notes UK 5-year action plan on AMR
01Nov18 07:00 RNS-R Destiny Pharma Plc -2.27%
Research collaboration with Southampton University
25Oct18 16:05 RNS Destiny Pharma Plc -2.27%
Grant of Options
25Oct18 07:00 RNS Destiny Pharma Plc -2.27%
Directorate Change
24Oct18 07:00 RNS-R Destiny Pharma Plc -2.27%
UK government highlights global threat of AMR
19Oct18 07:00 RNS-R Destiny Pharma Plc -2.27%
BIA celebrates UK bioscience innovative
26Sep18 07:00 RNS Destiny Pharma Plc -2.27%
Dr Jesús González appointed Chief Medical Officer
26Sep18 07:00 RNS Destiny Pharma Plc -2.27%
Interim results for six months ended 30 June 2018
06Sep18 07:00 RNS Destiny Pharma Plc -2.27%
Directorate Change
26Jul18 07:00 RNS Destiny Pharma Plc -2.27%
Positive Phase 1 skin irritation study with XF-73
17Jul18 07:00 RNS Destiny Pharma Plc -2.27%
Research collaboration with Aston University
11Jul18 07:00 RNS Destiny Pharma Plc -2.27%
Notice of Results
21Jun18 07:00 RNS Destiny Pharma Plc -2.27%
Directorate Change
05Jun18 12:47 RNS Destiny Pharma Plc -2.27%
Director/PDMR Shareholding
31May18 12:30 RNS Destiny Pharma Plc -2.27%
Result of AGM
23Apr18 07:00 RNS Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
12Apr18 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma announces clinical update on XF-73
12Apr18 07:00 RNS Destiny Pharma Plc -2.27%
Final Results
23Mar18 07:00 RNS Destiny Pharma Plc -2.27%
Notice of Full Year Results
22Mar18 07:00 RNS Destiny Pharma Plc -2.27%
Appointment of Joint Broker
15Mar18 07:00 RNS Destiny Pharma Plc -2.27%
FDA Fast Track Designation for lead drug XF-73
26Feb18 07:00 RNS Destiny Pharma Plc -2.27%
Destiny Pharma opens IND ahead of XF-73 US trials
Date / Time Company % Chg
10Jun21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma PLC - XF-73 data abstract to be presented at 2021 ECCMID
07Jun21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Destiny Pharma welcomes G7’s Communique on AMR
03Jun21 12:03 Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Result of AGM
02Jun21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Positive update on microbiome therapeutic NTCD-M3
25May21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Further information re AGM
19May21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma PLC - Notice to Register for 2021 AGM
06May21 10:00 Destiny Pharma Plc -2.27%
Conference Attendance for May 2021
04May21 07:00 Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
30Apr21 07:00 Destiny Pharma Plc -2.27%
Director Dealing
23Apr21 07:00 Destiny Pharma Plc -2.27%
Director Dealing
15Apr21 08:00 Destiny Pharma Plc -2.27%
FY 2020 Investor Presentation
14Apr21 07:00 Destiny Pharma Plc -2.27%
Final Results
29Mar21 12:45 Destiny Pharma Plc -2.27%
Exercise of Options and Total Voting Rights
29Mar21 12:00 Destiny Pharma Plc -2.27%
Destiny Pharma to Join Equity Development Webinar
29Mar21 10:15 Destiny Pharma Plc -2.27%
Exercise of Options and Total Voting Rights
29Mar21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma Reports Positive Phase 2b Results
16Mar21 07:00 Destiny Pharma Plc -2.27%
Notice of Results
15Mar21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma Announces Agreement with NIAID
10Mar21 14:15 Destiny Pharma Plc -2.27%
Exercise of Options and Total Voting Rights
10Mar21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
03Feb21 07:00 Destiny Pharma Plc -2.27%
Brazilian Patent Granted for XF-73 nasal gel
02Feb21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma Appoints Professor Mark Wilcox
21Jan21 16:31 Destiny Pharma Plc -2.27%
Grant of Share Options
21Jan21 08:28 Destiny Pharma Plc -2.27%
Destiny Pharma Investor Presentation
07Jan21 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma: Directors Dealings
06Jan21 08:00 Destiny Pharma Plc -2.27%
Destiny Pharma Appoints Stephanie Bewick as CBO
05Jan21 07:00 Destiny Pharma Plc -2.27%
Phase 2b trial of XF-73 completes recruitment
23Dec20 14:09 Destiny Pharma Plc -2.27%
Grant of share options
22Dec20 07:00 Destiny Pharma Plc -2.27%
Update on the recently acquired NTCD-M3 programme
01Dec20 17:23 Destiny Pharma Plc -2.27%
Holding(s) in Company
30Nov20 14:00 Destiny Pharma Plc -2.27%
Holding(s) in Company
26Nov20 10:50 Destiny Pharma Plc -2.27%
Result of General Meeting and Total Voting Rights
25Nov20 07:00 Destiny Pharma Plc -2.27%
Result of Open Offer
09Nov20 16:25 Destiny Pharma Plc -2.27%
Fundraising and Acquisition
12Oct20 07:00 Destiny Pharma Plc -2.27%
Clinical Study Patient Recruitment Update
17Sep20 07:00 Destiny Pharma Plc -2.27%
Update on Phase 2b clinical study of XF-73
17Sep20 07:00 Destiny Pharma Plc -2.27%
Interim results for the 6 months ended 30 Jun 2020
10Sep20 07:00 Destiny Pharma Plc -2.27%
Notice of Results
07Sep20 07:00 Destiny Pharma Plc -2.27%
Collaboration to co-develop treatment for COVID-19
11Aug20 07:00 Destiny Pharma Plc -2.27%
Positive interim safety review of XF-73 phase 2b
27Jul20 07:00 Destiny Pharma Plc -2.27%
Update on Phase 2b clinical study of XF-73
15Jul20 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma notes launch of AMR Action Fund
19Jun20 11:00 Destiny Pharma Plc -2.27%
Cancellation and Grant of Options
10Jun20 12:30 Destiny Pharma Plc -2.27%
Result of AGM
09Jun20 07:00 Destiny Pharma Plc -2.27%
Grant awarded for Cardiff University collaboration
12May20 15:15 Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
04May20 07:00 Destiny Pharma Plc -2.27%
Independent review supports the potential of XF-73
29Apr20 07:00 Destiny Pharma Plc -2.27%
Final Results
24Apr20 07:00 Destiny Pharma Plc -2.27%
Notice of Results
03Mar20 07:00 Destiny Pharma Plc -2.27%
Clinical and Business Update
20Jan20 07:00 Destiny Pharma Plc -2.27%
Update on the development of XF drug formulations
17Dec19 07:00 Destiny Pharma Plc -2.27%
APSIC guidelines recommend decolonising S. aureus
02Dec19 07:00 Destiny Pharma Plc -2.27%
Directorate Change
02Dec19 07:00 Destiny Pharma Plc -2.27%
Destiny to present at UK-China AMR Workshop
15Nov19 07:30 Destiny Pharma Plc -2.27%
Presentation at the Investival Showcase
06Nov19 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma to present at World AMR Congress
16Oct19 07:00 Destiny Pharma Plc -2.27%
Positive phase 1 results published in journal
23Sep19 07:00 Destiny Pharma Plc -2.27%
Directorate Change
23Sep19 07:00 Destiny Pharma Plc -2.27%
Interim Results for 6 months ended 30 June 2019
12Sep19 07:00 Destiny Pharma Plc -2.27%
Notice of Results
10Sep19 07:00 Destiny Pharma Plc -2.27%
University of Sheffield Research Collaboration
02Sep19 07:00 Destiny Pharma Plc -2.27%
XF Drug platform data presented at EuroBiofilms
15Aug19 12:20 Destiny Pharma Plc -2.27%
Holding(s) in Company
31Jul19 07:00 Destiny Pharma Plc -2.27%
Presentation at Gordon Research Conference
19Jul19 15:12 Destiny Pharma Plc -2.27%
Holding(s) in Company
04Jun19 14:39 Destiny Pharma Plc -2.27%
Grant of Options
04Jun19 12:06 Destiny Pharma Plc -2.27%
Result of AGM
09May19 14:06 Destiny Pharma Plc -2.27%
Appointment of NOMAD and Joint Broker
29Apr19 14:28 Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
09Apr19 07:00 Destiny Pharma Plc -2.27%
Final Results
05Apr19 17:06 Destiny Pharma Plc -2.27%
Exercise of Options
01Apr19 15:03 Destiny Pharma Plc -2.27%
Exercise of Options
28Mar19 18:13 Destiny Pharma Plc -2.27%
Exercise of Options
27Mar19 07:00 Destiny Pharma Plc -2.27%
MedPharm to develop new XF-drug formulations
22Mar19 09:47 Destiny Pharma Plc -2.27%
Notice of Results
06Mar19 18:00 Destiny Pharma Plc -2.27%
Exercise of Options
28Jan19 07:00 Destiny Pharma Plc -2.27%
Second positive phase 1 trial data for XF-73
25Jan19 07:00 Destiny Pharma Plc -2.27%
New grant awarded under UK-China AMR programme
24Jan19 11:50 Destiny Pharma Plc -2.27%
Destiny Pharma notes UK 5-year action plan on AMR
01Nov18 07:00 Destiny Pharma Plc -2.27%
Research collaboration with Southampton University
25Oct18 16:05 Destiny Pharma Plc -2.27%
Grant of Options
25Oct18 07:00 Destiny Pharma Plc -2.27%
Directorate Change
24Oct18 07:00 Destiny Pharma Plc -2.27%
UK government highlights global threat of AMR
19Oct18 07:00 Destiny Pharma Plc -2.27%
BIA celebrates UK bioscience innovative
26Sep18 07:00 Destiny Pharma Plc -2.27%
Dr Jesús González appointed Chief Medical Officer
26Sep18 07:00 Destiny Pharma Plc -2.27%
Interim results for six months ended 30 June 2018
06Sep18 07:00 Destiny Pharma Plc -2.27%
Directorate Change
26Jul18 07:00 Destiny Pharma Plc -2.27%
Positive Phase 1 skin irritation study with XF-73
17Jul18 07:00 Destiny Pharma Plc -2.27%
Research collaboration with Aston University
11Jul18 07:00 Destiny Pharma Plc -2.27%
Notice of Results
21Jun18 07:00 Destiny Pharma Plc -2.27%
Directorate Change
05Jun18 12:47 Destiny Pharma Plc -2.27%
Director/PDMR Shareholding
31May18 12:30 Destiny Pharma Plc -2.27%
Result of AGM
23Apr18 07:00 Destiny Pharma Plc -2.27%
Posting of Annual Report and Notice of AGM
12Apr18 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma announces clinical update on XF-73
12Apr18 07:00 Destiny Pharma Plc -2.27%
Final Results
23Mar18 07:00 Destiny Pharma Plc -2.27%
Notice of Full Year Results
22Mar18 07:00 Destiny Pharma Plc -2.27%
Appointment of Joint Broker
15Mar18 07:00 Destiny Pharma Plc -2.27%
FDA Fast Track Designation for lead drug XF-73
26Feb18 07:00 Destiny Pharma Plc -2.27%
Destiny Pharma opens IND ahead of XF-73 US trials